Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center

Shuji Murakami1, Yukihiko Hiroshima2, Seigo Katakura1

  • 1Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.

Thoracic Cancer
|June 2, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Amplicon-Based Next-Generation Sequencing Testing and Immunohistochemical Staining in Detecting <i>Anaplastic Lymphoma Kinase</i> Fusion Genes in Non-Small-Cell Lung Cancer: A Large Single-Centre Cohort Study.

Cancers·2026
Same author

Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

Cancer science·2026
Same author

Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma.

JCO precision oncology·2026
Same author

A Three-Dimensional Culture-Drug Sensitivity Test Predicts MDM2 Inhibitor-Sensitivity in SMARCB1/INI1-Deficient Tumors.

Cancer science·2026
Same author

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Utility of AMOY polymerase chain reaction panel in detecting non-small cell lung cancer using pleural cell block.

Japanese journal of clinical oncology·2026

Comprehensive genomic profiling (CGP) identified actionable mutations in advanced non-small cell lung cancer (NSCLC) missed by standard tests. This approach may offer new therapeutic options for patients, particularly non-smokers.

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Standard care for advanced non-small cell lung cancer (NSCLC) involves multiplex companion diagnostics for biomarker testing.
  • Challenges persist in identifying rare mutations and resistance mechanisms post-targeted therapy.
  • This study assessed the utility of comprehensive genomic profiling (CGP) for detecting druggable genetic aberrations after standard treatment.

Purpose of the Study:

  • To evaluate the prevalence of druggable genetic aberrations in advanced NSCLC.
  • To determine the clinical utility of CGP in real-world practice.
  • To identify potential therapeutic opportunities missed by conventional diagnostics.

Main Methods:

  • Retrospective analysis of 108 advanced or recurrent NSCLC patients.
Keywords:
ErbB receptorsbiopsyhigh‐throughput nucleotide sequencingmutationnon‐small cell lung carcinoma

Related Experiment Videos

Last Updated: Jun 3, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

  • CGP performed using OncoGuide NCC Oncopanel System, FoundationOne, and FoundationOne Liquid.
  • Data collected between January 2019 and December 2023 at Kanagawa Cancer Center Hospital, Japan.

    • Main Results:

    • Druggable genetic aberrations found in 37% of patients; EGFR mutations were most common.
    • Resistance mechanisms identified in 9/19 patients after re-biopsy.
    • Non-smokers showed a higher rate of druggable mutations (55.6%) than smokers (27.8%).
    • Genomically matched therapy showed a trend towards prolonged overall survival (p=0.054).

    Conclusions:

    • CGP testing identifies actionable mutations missed by conventional diagnostics in NSCLC.
    • CGP may offer additional therapeutic opportunities for NSCLC patients.
    • The findings support CGP's role in guiding treatment decisions for advanced NSCLC.